Astellas Pharma Inc. and its US subsidiary, Astellas Pharma US, Inc. ("Astellas") and Teva Pharmaceutical USA, Inc. ("Teva") announced today that the three companies have reached an agreement to settle the pending U.S. litigation with regard to US Patent No. 6,017,927 for VESIcare® (solifenacin succinate) tablet through the entry of a consent judgment.   VESIcare is a treatment for the overactive bladder. 

As a result of this settlement, the case will be terminated by the consent judgment. The settlement of the litigation provides Teva with the opportunity to launch a generic solifenacin succinate product in October, 2018 if Astellas does not obtain pediatric exclusivity. Further terms of the settlement will not be disclosed.

Contact the Media Relations team
Corporate Advocacy & Relations
Main phone line for Media: +81-3244-3201 
Business hours (JST)
From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm
(closed on Saturdays, Sundays, national holidays and company holidays)